AI Summary & Key Takeaways
AI InsightWe concluded that PAPP-A may increase the bioavailability of insulin-like growth factors (IGFs) due to decreased neurogenesis and synthesis of IGFs in chronically epilepsy patients.
📌 3 Key Takeaways
Abstract
In this study, we aimed to investigate the role of pregnancy-associated plasma protein-A (PAPP-A) as insulin-like growth factor binding protein-4 (IGFBP-4) protease in epilepsy patients. We studied 16 epilepsy patients and 10 healthy controls. Serum PAPP-A levels of epilepsy patients (6.8 ± 3.2 mU/L) were higher than of the control group (5.1 ± 1.9 mU/L), but the difference was not statistically significant (P > 0.05). We concluded that PAPP-A may increase the bioavailability of insulin-like growth factors (IGFs) due to decreased neurogenesis and synthesis of IGFs in chronically epilepsy patients.
Özet
In this study, we aimed to investigate the role of pregnancy-associated plasma protein-A (PAPP-A) as insulin-like growth factor binding protein-4 (IGFBP-4) protease in epilepsy patients. We studied 16 epilepsy patients and 10 healthy controls. Serum PAPP-A levels of epilepsy patients (6.8 ± 3.2 mU/L) were higher than of the control group (5.1 ± 1.9 mU/L), but the difference was not statistically significant (P > 0.05). We concluded that PAPP-A may increase the bioavailability of insulin-like growth factors (IGFs) due to decreased neurogenesis and synthesis of IGFs in chronically epilepsy patients.